going places

Houston female-founded startup takes on national expansion

Work & Mother — with the help of CBRE Group Inc. — is gearing up for a national expansion. Photo courtesy of Work & Mother

Houston-based Work & Mother Services LLC is embarking on a nationwide expansion of its network of lactation suites.

Work & Mother already operates two locations in downtown Houston (The Jones on Main and Three Allen Center) and is preparing to open locations at Four Oaks Place in Houston and Eastlake at Tillery in Austin. Beyond that growth, the company aims to expand to metro areas like Dallas-Fort Worth, Chicago, Los Angeles, and New York City.

Work & Mother has tapped Abby Alford and Lucian Bukowski of commercial real estate services company CBRE Group Inc. to find space in expansion markets. Both of them work out of CBRE's office on Post Oak Boulevard.

Work & Mother's lactation suites feature private rooms, hospital-grade pumps, and refrigeration and storage options. As part of its service, the company offers a booking app and support resources, such as lactation consultants and career coaches, to working mothers who are breastfeeding their babies.

"Most employers have a legal obligation to provide a proper space for nursing mothers, but pumping at work has always been incredibly difficult, with in-office solutions and multipurpose wellness rooms often failing moms and contributing to high turnover rates around motherhood — many employers don't even realize they have a problem until it's too late," Abbey Donnell, founder and CEO of Work & Mother, says in a CBRE news release.

"We look forward to supporting more new mothers' return to work and providing the real estate services that office tenants and landlords need in a post-pandemic world to promote wellness, flexibility, and inclusion in the workplace," Donnell adds.

A Work & Mother suite is an amenity shared by tenants of an office building. The company says its suites help employers adhere to federal labor laws, reduce HR risks, and retain female employees.

"The pandemic has forced tenants and landlords alike to reimagine workplaces with a greater focus on employee experience in order to recruit and retain top talent," CBRE's Alford says.

Donnell, a Rice University alumna, started her company in 2017. She is a certified lactation counselor and a former advertising executive.

Earlier this year, Work & Mother raised an undisclosed amount of funding from The Artemis Fund, a Houston-based firm that supports women-led startups; the Texas HALO Fund, a Houston-based investment firm; and the Beam Angel Network, an Austin-based nonprofit that backs startups founded by women.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted